BR112022016470A2 - Formulação de dosagem farmacêutica, e, métodos para diminuir a glicemia de um mamífero e para induzir perda de peso em um mamífero - Google Patents
Formulação de dosagem farmacêutica, e, métodos para diminuir a glicemia de um mamífero e para induzir perda de peso em um mamíferoInfo
- Publication number
- BR112022016470A2 BR112022016470A2 BR112022016470A BR112022016470A BR112022016470A2 BR 112022016470 A2 BR112022016470 A2 BR 112022016470A2 BR 112022016470 A BR112022016470 A BR 112022016470A BR 112022016470 A BR112022016470 A BR 112022016470A BR 112022016470 A2 BR112022016470 A2 BR 112022016470A2
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- methods
- blood glucose
- weight loss
- pharmaceutical dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980093P | 2020-02-21 | 2020-02-21 | |
| US202063122108P | 2020-12-07 | 2020-12-07 | |
| US202163133540P | 2021-01-04 | 2021-01-04 | |
| PCT/US2021/018947 WO2021168386A1 (en) | 2020-02-21 | 2021-02-21 | Glp-1r and gcgr agonists, formulations, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016470A2 true BR112022016470A2 (pt) | 2022-11-22 |
Family
ID=77391258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016470A BR112022016470A2 (pt) | 2020-02-21 | 2021-02-21 | Formulação de dosagem farmacêutica, e, métodos para diminuir a glicemia de um mamífero e para induzir perda de peso em um mamífero |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210290732A1 (https=) |
| EP (1) | EP4106796A4 (https=) |
| JP (2) | JP7752619B2 (https=) |
| KR (1) | KR20220143923A (https=) |
| CN (1) | CN115427065A (https=) |
| AU (1) | AU2021224246A1 (https=) |
| BR (1) | BR112022016470A2 (https=) |
| CA (1) | CA3168001A1 (https=) |
| IL (1) | IL295744A (https=) |
| MX (1) | MX2022010320A (https=) |
| WO (1) | WO2021168386A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108892709A (zh) * | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | 改良的肽药物 |
| MX360816B (es) * | 2012-11-20 | 2018-11-15 | Mederis Diabetes Llc | Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. |
| US20230317230A1 (en) * | 2019-05-02 | 2023-10-05 | Closed Loop Medicine Ltd. | Method for treating obesity |
| CN117202924A (zh) * | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| CN118234742A (zh) * | 2021-12-01 | 2024-06-21 | 江苏恒瑞医药股份有限公司 | Glp-1和gip受体双重激动剂的药物组合物及其用途 |
| JP2025537192A (ja) * | 2022-11-05 | 2025-11-14 | スピットファイア ファーマ エルエルシー | Ｇｌｐ－１ｒおよびｇｃｇｒアゴニストを使用した心血管リスク因子の処置のための治療レジメンおよび方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008513384A (ja) * | 2004-09-17 | 2008-05-01 | ノボ ノルディスク アクティーゼルスカブ | インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物 |
| MX2007005521A (es) * | 2004-11-12 | 2007-05-18 | Novo Nordisk As | Formulaciones estables de peptidos insulinotropicos. |
| CN108892709A (zh) * | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | 改良的肽药物 |
| MX360816B (es) * | 2012-11-20 | 2018-11-15 | Mederis Diabetes Llc | Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. |
| ES2906975T3 (es) * | 2012-11-20 | 2022-04-21 | Eumederis Pharmaceuticals Inc | Productos farmacéuticos de péptidos mejorados |
| EP2986313B1 (en) * | 2013-04-18 | 2019-06-12 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| PT3155017T (pt) * | 2014-05-28 | 2024-05-14 | Mederis Diabetes Llc | Farmacêuticos peptídicos melhorados para resistência à insulina |
| JP2017517549A (ja) * | 2014-06-13 | 2017-06-29 | サノフイ | 活性薬剤成分のナノカプセル製剤 |
| PE20170471A1 (es) * | 2014-06-13 | 2017-05-14 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados |
| AU2015320545C1 (en) * | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| EP4523705A3 (en) * | 2015-06-30 | 2025-06-11 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| CN108718522A (zh) * | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | Il-6拮抗剂制剂及其用途 |
| EP4506017A3 (en) * | 2018-01-03 | 2025-05-14 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
-
2021
- 2021-02-21 CA CA3168001A patent/CA3168001A1/en active Pending
- 2021-02-21 WO PCT/US2021/018947 patent/WO2021168386A1/en not_active Ceased
- 2021-02-21 IL IL295744A patent/IL295744A/en unknown
- 2021-02-21 EP EP21757069.6A patent/EP4106796A4/en active Pending
- 2021-02-21 AU AU2021224246A patent/AU2021224246A1/en active Pending
- 2021-02-21 CN CN202180029769.4A patent/CN115427065A/zh active Pending
- 2021-02-21 MX MX2022010320A patent/MX2022010320A/es unknown
- 2021-02-21 JP JP2022548518A patent/JP7752619B2/ja active Active
- 2021-02-21 US US17/180,827 patent/US20210290732A1/en active Pending
- 2021-02-21 KR KR1020227032683A patent/KR20220143923A/ko active Pending
- 2021-02-21 BR BR112022016470A patent/BR112022016470A2/pt unknown
-
2025
- 2025-01-22 US US19/034,251 patent/US20250262280A1/en active Pending
- 2025-09-29 JP JP2025162266A patent/JP2026021305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021224246A1 (en) | 2022-09-15 |
| US20210290732A1 (en) | 2021-09-23 |
| JP2026021305A (ja) | 2026-02-10 |
| CN115427065A (zh) | 2022-12-02 |
| EP4106796A4 (en) | 2024-04-17 |
| US20250262280A1 (en) | 2025-08-21 |
| EP4106796A1 (en) | 2022-12-28 |
| IL295744A (en) | 2022-10-01 |
| JP2023514992A (ja) | 2023-04-12 |
| CA3168001A1 (en) | 2021-08-26 |
| JP7752619B2 (ja) | 2025-10-10 |
| KR20220143923A (ko) | 2022-10-25 |
| MX2022010320A (es) | 2023-01-30 |
| WO2021168386A1 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022016470A2 (pt) | Formulação de dosagem farmacêutica, e, métodos para diminuir a glicemia de um mamífero e para induzir perda de peso em um mamífero | |
| BR112022009287A2 (pt) | Agonista do receptor de glp-1 e uso do mesmo | |
| Nel et al. | Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel | |
| BR112013003186A2 (pt) | composições e métodos para tratamento de doença cardiovascular | |
| CO5271709A1 (es) | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos | |
| Hu et al. | Effects of autologous adipose-derived stem cell infusion on type 2 diabetic rats | |
| GT200800037A (es) | Solucion de cloruro de sodio para reconstitucion o dilucion de farmacos | |
| AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
| Pojednic et al. | Vitamin D receptor protein is associated with interleukin-6 in human skeletal muscle | |
| BR112023019201A2 (pt) | Composição farmacêutica aquosa ou composição farmacêutica liofilizada | |
| Kassimatis et al. | Ex vivo delivery of Mirococept: A dose-finding study in pig kidney after showing a low dose is insufficient to reduce delayed graft function in human kidney | |
| BR112022016456A2 (pt) | Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos | |
| BR112022013725A2 (pt) | Formulações para agentes terapêuticos proteicos | |
| Sunderkötter et al. | Immunohistochemical detection of bFGF and TNF-alpha in the course of inflammatory angiogenesis in the mouse cornea | |
| Okan et al. | Fibroblast growth factor 23 and placental growth factor in patients with psoriasis and their relation to disease severity | |
| AU2016323541A1 (en) | Mammalian follicle-stimulating hormone composition with increased stability | |
| JOP20230150A1 (ar) | صيغ ببتيد علاجية | |
| Bloch et al. | Hyper-activation of endogenous GLP-1 system to gram-negative sepsis is associated with early innate immune response and modulated by diabetes | |
| Belmiro et al. | Dermatan sulfate reduces monocyte chemoattractant protein 1 and TGF-β production, as well as macrophage recruitment and myofibroblast accumulation in mice with unilateral ureteral obstruction | |
| Yuki et al. | Endothelin-1 stimulates cardiomyocyte injury during mitochondrial dysfunction in culture | |
| Raut et al. | An evaluation of the effects of nonselective and cardioselective β-blockers on wound healing in Sprague Dawley rats | |
| Kogiso et al. | Role of PPARγ in COX-2 activation in mycobacterial pulmonary inflammation | |
| Akdag et al. | Urolithin B reduces the aggregate load of islet amyloid polypeptide in Caenorhabditis elegans | |
| Vantomme et al. | Visual impairment related to an isolated paracentral cotton wool spot revealing an atypical presentation of Bartonella henselae retinitis | |
| CL2008001936A1 (es) | Composicion vacunal que comprende un conjugado quimico entre el factor de crecimiento epidermico humano recombinante (hregf) y la proteina recombinante rp64k; donde cada molecula de rp64k se enlaza 2 moleculas de hregf, con al menos un 90% de principio activo;procedimiento de obtencion; y su uso para tratar tumores de origen epitelial. |